Compare AbbVie Inc (ABBV) vs Logitech International SA (LOGI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Logitech International SA — how do they compare? AbbVie Inc trades at $253.95 (market cap $449.91B), while Logitech International SA trades at $96.39 (market cap $13.85B). The key difference: AbbVie Inc is far larger — about 32.5× Logitech International SA's market cap, and AbbVie Inc pays the higher dividend (2.72%). Which is the better fit depends on your goals.
| ABBV | LOGI | |
|---|---|---|
Market Cap | $449.91B | $13.85B |
Sector | Health | Technology |
52-Week High | $261.07 | $126.69 |
52-Week Low | $184.85 | $85.84 |
Enterprise Value | $513.38B | $12.20B |
Dividend Yield | 2.72% | 1.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $254.44, showing slight daily weakness but maintaining a bullish technical structure with strong institutional support. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $2.65 exceeding the $2.59 estimate. Revenue growth is accelerating, reaching $61.16B in 2025, while the immunology portfolio (Skyrizi, Rinvoq) successfully offsets Humira declines. Analyst consensus remains strongly positive with 68% buy ratings and a $266.33 price target.
The outlook is constructive with robust pipeline developments and dividend growth, though elevated valuation multiples (P/E 124.83, P/B 245.29) and looming patent cliffs in the 2030s present risks. Net income margin compression from 20.38% in 2022 to 6.9% in 2025 requires monitoring, but strong cash generation ($19.03B operating cash flow) supports continued shareholder returns.
Logitech (LOGI) trades at $97.11, up 3.31% with strong profitability metrics including 43.2% gross margin and 32.78% ROE. The stock shows bearish technical signals despite recent earnings beats, with Q1 2026 EPS of $1.13 exceeding expectations. Recent developments include new gaming partnerships and product launches like the G3 Series and Mobi Fold mouse. Cash flow trends show operational strength with $843M generated in 2025, though net cash flow was slightly negative at -$18M.
Logitech presents a mixed outlook with robust fundamentals offset by technical weakness. The 26% upside to consensus price target of $121.33 offers potential, but bearish moving averages and competitive pressures in peripherals market pose risks. Enterprise momentum and AI-enabled products provide growth catalysts, though investor sentiment remains divided with equal buy/sell analyst ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Logitech International SA
Logitech International SA is a Switzerland-based provider of personal computer and mobile accessories for navigation, video communication, and collaboration, smart home, and other applications. Its product portfolio includes mice, keyboards, charging stands, tablet cases, car mounts for mobile devices, remotes, home cameras, home switches, controllers, bluetooth speakers, surround sound, webcams, and conference cameras. It operates in a single segment namely, Peripherals. The firm generates revenue from the Americas, EMEA (Europe, Middle East, Africa), and the Asia Pacific region.
Read more on LOGI →
